Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT003 vs Placebo on Airway Volumes in COPD
NCT02643082Phase 3Completed
- Sponsor
- Pearl Therapeutics
- Start
- Dec 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of glycopyrronium, formoterol fumarate in chronic obstructive pulmonary disease (COPD), sponsored by Pearl Therapeutics. Started Dec 2015; status: completed.
02
Drugs
glycopyrroniumformoterol fumarate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02643082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02643082.